The brainchild of serial biotech entrepreneur Michael Gilman, Obsidian is hoping to bring something new to the party with “on-switch” technology for a range of potential drug applications. Obsidian now has a new treasure chest to play with — and an IPO feels only a fingertip away. Obsidian closed a $115 million Series B with […]

Unlike most other industries, in science it helps to work with your friends – that’s a quote from Dr. Jonathan Rothbard, CSO of 180 Life Sciences (NASDAQ:ATNF), who joins the podcast with ATNF co-founder Prof Sir Marc Feldmann, who co-founded the company with Professor Raphael Mechoulam (known for his discovery of tetrahydrocannabinol (THC), the psychoactive part […]

From the Stanford University lab of a cancer immunotherapy pioneer to an IPO, a small-but-growing Peninsula biotech company is looking to continue its win streak with its third biopharma collaboration of the year. Bolt Biotherapeutics Inc. of Redwood City said it will partner with drug giant Bristol-Myers Squibb Co. on a new combination of two […]